IMMUNE CHECKPOINT INHIBITORS

This trial asks whether giving sintilimab, an immune checkpoint inhibitor, after complete surgical removal of non-small cell lung cancer can improve outcomes for patients at high risk of recurrence. Participants who already received chemotherapy plus an immune checkpoint inhibito…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder cancer surgery is safe and effective. About 150 people with muscle-invasive bladder cancer will receive durvalumab plus either ddMVAC or gemcitabine/cisplatin chemo…

This phase 2 trial tests whether adding the immunotherapy drug serplulimab to standard chemotherapy before surgery helps patients with advanced stomach or gastroesophageal junction cancer. About 116 participants will receive either the combo or chemo alone for three cycles before…

This study is testing whether immune checkpoint inhibitors, drugs that help the immune system fight infections, can improve outcomes for people with progressive multifocal leukoencephalopathy (PML), a rare brain virus. Researchers will follow 66 patients over a year, measuring di…

This study investigates why some advanced or recurrent endometrial cancers respond to immunotherapy while others do not. Researchers will collect tumor samples from 510 patients before they start immunotherapy and use lab-grown tumor models to study molecular and genetic features…

This study aims to understand how rheumatic side effects (like arthritis) from cancer immunotherapy affect patients' daily lives. Researchers will interview 20 adults who have experienced these side effects to learn about their severity and impact. The goal is to improve future c…